We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Regeneron Pharmaceuticals Inc | NASDAQ:REGN | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 19.39 | 2.07% | 957.00 | 954.85 | 990.00 | 958.13 | 926.94 | 926.94 | 547,374 | 05:00:06 |
From May 2019 to May 2024
By Colin Kellaher
Regeneron Pharmaceuticals Inc. (REGN) on Thursday reported positive topline phase 2 data for pozelimab in patients with the rare blood disorder paroxysmal nocturnal hemoglobinuria, or PNH.
The Tarrytown, N.Y., biotechnology company, said results from initial six-patient cohort show pozelimab reduced the abnormal destruction of red blood cells, known as hemolysis, with patients achieving normal levels of a blood biomarker of elevated hemolysis called lactate dehydrogenase.
Regeneron said it has initiated the second part of the phase 2 trial, adding that plans for a phase 3 program are underway.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
December 05, 2019 09:25 ET (14:25 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year Regeneron Pharmaceuticals Chart |
1 Month Regeneron Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
